Associations Between Serum Inflammatory Markers and Hippocampal Volume in a Community Sample

Journal of the American Geriatrics Society

Volumn 64, Issue 9, 2016, Pages 1823-1829

  Schmidt, Mike F ^a,b   Freeman, Kevin B ^b   Windham, Beverly G ^b   Griswold, Michael E ^a   Kullo, Iftikhar J ^c   Turner, Stephen T ^c   Mosley, Thomas H ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

hippocampus; inflammation; TNF

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD; BRAIN SIZE; CAUCASIAN; COMMUNITY SAMPLE; FEMALE; HIPPOCAMPUS; HUMAN; INFLAMMATION; MALE; MINNESOTA; MISSISSIPPI;

EID: 84987849637     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14283     Document Type: Article

References (48)

1. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004;39:687–699.
2. Godbout JP, Johnson RW. Interleukin-6 in the aging brain. J Neuroimmunol 2004;147:141–144.
3. Yaffe K, Lindquist K, Penninx BW et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76–80.
4. Weaver JD, Huang M-H, Albert M et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002;59:371–378.
5. Wright CB, Sacco RL, Rundek TR et al. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. J Stroke Cerebrovasc Dis 2006;15:34–38.
6. Windham BG, Simpson BN, Lirette S et al. Associations between inflammation and cognitive function in African Americans and European Americans. J Am Geriatr Soc 2014;62:2303–2310.
7. Teunissen CE, van Boxtel MPJ, Bosma H et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003;134:142–150.
8. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009;33:355–366.
9. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383–421.
10. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease: a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2:a006346.
11. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013;126:479–497.
12. Teunissen CE, de Vente J, Steinbusch HWM et al. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002;23:485–508.
13. Swardfager W, Lanctôt K, Rothenburg L et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68:930–941.
14. Kálmán J, Juhász A, Laird G et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand 1997;96:236–240.
15. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. J Psychiatr Res 1997;31:657–660.
16. Licastro F, Candore G, Lio D et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005;2:8.
17. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000;20:1057–1060.
18. Schmidt R, Schmidt H, Curb JD et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168–174.
19. Jefferson AL, Massaro JM, Wolf PA et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007;68:1032–1038.
20. Schram MT, Euser SM, de Craen AJM et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007;55:708–716.
21. Gimeno D, Marmot MG, Singh-Manoux A. Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008;33:1322–1334.
22. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178–201.
23. Montagne A, Barnes SR, Sweeney MD et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015;85:296–302.
24. Squire LR, Stark CEL, Clark RE. The medial temporal lobe. Annu Rev Neurosci 2004;27:279–306.
25. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 2006;30:730–748.
26. Raz N, Lindenberger U, Rodrigue KM et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15:1676–1689.
27. Marsland AL, Gianaros PJ, Abramowitch SM et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008;64:484–490.
28. Kim CX, Bailey KR, Klee GG et al. Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS ONE 2010;5:e9065.
29. Tang MX, Stern Y, Marder K et al. The APOE-e4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751–755.
30. Green RC, Cupples LA, Go R et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287:329–336.
31. FBPP Investigators. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension 2002;39:3–9.
32. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989;129:687–702.
33. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266–274.
34. Aderka D, Sorkine P, Abu-Abid S et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. J Clin Invest 1998;101:650–659.
35. Ellington AA, Kullo IJ, Bailey KR et al. Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem 2009;55:1092–1099.
36. Knopman DS, Mosley TH, Bailey KR et al. Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. J Neurol Sci 2008;271:53–60.
37. Jack CR, O'Brien PC, Rettman DW et al. FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging 2001;14:668–676.
38. Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–355.
39. Fischl B. FreeSurfer. NeuroImage 2012;62:774–781.
40. Koyama A, O'Brien J, Weuve J et al. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci 2013;68A:433–440.
41. McCusker SM, Curran MD, Dynan KB et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 2001;357:436–439.
42. Tan ZS, Beiser AS, Vasan RS et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007;68:1902–1908.
43. Sundelöf J, Kilander L, Helmersson J et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009;18:79–87.
44. Tarkowski E, Blennow K, Wallin A et al. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999;19:223–230.
45. Jefferson AL, Massaro JM, Beiser AS et al. Inflammatory markers and neuropsychological functioning: the Framingham Heart Study. Neuroepidemiology 2011;37:21–30.
46. Aderka D, Engelmann H, Shemer-Avni Y et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992;11:157–159.
47. Tilg H, Trehu E, Atkins MB et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113–118.
48. Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 2004;61:668–672.